Neva SGR invests in next-generation cancer diagnosis and treatment technologies

18 July 2025

Neva SGR, the Intesa Sanpaolo Group’s venture capital company and a wholly owned subsidiary of Intesa Sanpaolo Innovation Center, has participated in a CHF 79 million (€84 million) funding round for NUCLIDIUM.

NUCLIDIUM is a Swiss-German biotech company specialising in next-generation copper isotope-based radiopharmaceuticals to treat cancer.

The investment will enable NUCLIDIUM to accelerate the development of its innovative copper-based theranostics platform, which offers an integrated approach to cancer diagnosis and treatment, with more precise targeting that reduces damage to healthy tissue.

The investment aligns with Neva SGR’s strategy of investing in high-growth companies with innovative projects addressing major global challenges, including the fight against cancer.

Neva SGR will contribute to NUCLIDIUM’s growth and foster collaboration with clinical facilities, research centres and Italian companies in the sector.

Since August 2020, Neva SGR has met its initial goals with its first three Funds: Neva First, for global investments; Neva First Italia, dedicated to national enterprises, and Fondo Sei, focused on developing Italian innovation ecosystems. It has invested almost €190 million in 43 fast-growing, innovative companies, distributing around €13 million to its investor.

In addition, though the new Neva II and Neva II Italia funds, it has already invested a further €45 million in five companies.